Vaccine Info

Rabivax-S Rabies Vaccine

Authored by
Last reviewed
May 17, 2023

Rabivax-S Rabies Vaccine May 2023

Rabivax-S has been developed on Vero ATCC CCL81 cells using Pitman Moore (PM3218) strain. It is an inactivated vaccine that is freeze-dried until ready for immunization. The vaccine was tested in a GLP toxicology study following all the GMP requirements. Further, it underwent clinical trials in preexposure and postexposure settings and was found safe and immunogenic.

Rabies vaccines like RabAvert, Rabipur, or Rabivax efficiently induce long-lasting immunity, triggering neutralizing antibodies' production, but several doses are required. Regrettably, rabies vaccination is not included in the vaccines covered by the Expanded Programme on Immunization, and they are expensive and not affordable in developing countries.

Serum Institute of India Pvt. Ltd. (SII) is an Indian biotechnology and biopharmaceutical company that produces Rabivax-S.

Rabivax-S Indication

RABIVAX-S is indicated for the prevention of rabies in children and adults. It can be used before or after exposure, as a primary immunization, or as a booster dose. Rabivax is administered intramuscular and/or intra-dermal. Suppose an individual who has been fully immunized in the past is exposed to Rabies. In that case, the recommended PEP schedule is one dose of Rabies vaccine injected intramuscularly (1 ml) or intradermally (0.1 ml) on day 0 and day 3.

Rabivax-S News

May 20, 2022 - Improper vaccinations could re-introduce rabies into the U.S., warned the Centers for Disease Control and Prevention.

October 20, 2020 - An Overview of Current Uses and Future Opportunities for Computer-Assisted Design of Vaccines for Neglected Tropical Diseases.

March 3, 2017 - Study: Development of a new purified Vero cell rabies vaccine (Rabivax-S) at the Serum Institute of India Pvt Ltd.

September 14, 2016 - A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes. Conclusions: Rabivax-S was well tolerated and showed immunogenicity comparable to a licensed rabies vaccine by both IM and ID routes in post-exposure prophylaxis.

Rabivax-S Clinical Trials

Clinical Trial NCT03741270: Safety of Rabivax-S for Preexposure Prophylaxis: Last Update Posted: September 24, 2019.

People with frequent or continuous rabies virus exposure should be vaccinated against the disease (preexposure prophylaxis). This includes people who work with rabies virus in research or diagnostic laboratories or vaccine production facilities, veterinarians, staff, animal control, and wildlife workers in areas where rabies is endemic. Veterinary students in clinical placements and externships are included in this category, DVM students at Ross University School of Veterinary Medicine (RUSVM) are vaccinated against rabies in their 7th semester (final pre-clinical semester). Vaccinations are done by RUSVM Health Services using Rabivax-S, produced by the Serum Institute of India (study co-sponsors). Previously unvaccinated studentreceivedve three vaccine injections on days 0, 7, and 21-28. The study aims to generate additional data on the safety and tolerability of Rabivax-S administered as preexposure prophylaxis to this population.